Bellerophon Therapeutics (NASDAQ:BLPH) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research note published on Saturday morning. The firm issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

Bellerophon Therapeutics stock opened at $0.05 on Friday. Bellerophon Therapeutics has a 1 year low of $0.03 and a 1 year high of $0.52. The firm has a 50 day moving average price of $0.06 and a 200 day moving average price of $0.06. The company has a market cap of $623,730.00, a price-to-earnings ratio of -0.06 and a beta of 0.73.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.